Review Article
C lostridium difficile is an anaerobic gram-positive, spore-forming, toxin-producing bacillus that is transmitted among humans through the fecaloral route. The relationship between the bacillus and humans was once thought to be commensal, 1 but C. difficile has emerged as a major enteric pathogen with worldwide distribution. In the United States, C. difficile is the most frequently reported nosocomial pathogen. A surveillance study in 2011 identified 453,000 cases of C. difficile infection and 29,000 deaths associated with C. difficile infection; approximately a quarter of those infections were community-acquired. 2 Nosocomial C. difficile infection more than quadruples the cost of hospitalizations, 3 increasing annual expenditures by approximately $1.5 billion in the United States. 4 In this article, we review the changing epidemiology of this infection, discuss risk factors and preventive strategies, outline current recommendations for treatment, and highlight developing strategies for disease control.
Pathogenesis a nd Epidemiol ogy
C. difficile colonizes the large intestine and releases two protein exotoxins (TcdA and TcdB) that cause colitis in susceptible persons. Infection is transmitted by spores that are resistant to heat, acid, and antibiotics. The spores are plentiful in health care facilities and are found in low levels in the environment and food supply, allowing for both nosocomial and community transmission. 5 Colonization is prevented by barrier properties of the fecal microbiota; weakening of this resistance by antibiotics is the major risk factor for disease ( Fig. 1 ). Advanced age, antineoplastic chemotherapy, and severe underlying disease also contribute to susceptibility. Symptoms of colitis do not develop in all colonized persons. For example, the majority of infants are colonized with C. difficile but are asymptomatic, [6] [7] [8] possibly owing to the lack of toxin-binding receptors in the infant gut, as shown in animal models 9 and as suggested by the common development of antibodies to C. difficile toxins in infants without clinical infection. 7 C. difficile diarrhea is mediated by TcdA and TcdB, which inactivate members of the Rho family of guanosine triphosphatases (Rho GTPases), leading to colonocyte death, loss of intestinal barrier function, and neutrophilic colitis. The organism itself is noninvasive, and infection outside the colon is extremely rare. The two factors that exert a major influence on clinical expression of disease are the virulence of the infecting strain and the host immune response. In the early 2000s, hospitals began reporting dramatic increases in severe C. difficile infection. Isolates were characterized by the Centers for Disease Control and Prevention as toxinotype III, restriction endonuclease analysis group BI, North American pulsed-field gel electrophoresis type NAP1, and polymerase-chain-reaction (PCR) type 027 and were subsequently known as BI/NAP1/027. 10 The BI/NAP1/027 strain is characterized by high-level fluoroquinolone resistance, efficient sporulation, markedly high n engl j med 372;16 nejm.org April 16, 2015 T h e ne w e ngl a nd jou r na l o f m e dicine toxin production, 11, 12 and a mortality rate three times as high as that associated with less virulent strains, such as the 001 or 014 ribotypes. 13, 14 Asymptomatic colonization with toxigenic C. difficile in infants stimulates a durable immune response that appears to protect against symptomatic infection later in life. 7 For example, high titers of serum IgG antitoxins to TcdA and TcdB are associated with asymptomatic colonization in hospitalized patients exposed to antibiotics. 15 Immunization of experimental animals with TcdA is also protective, 16 and passive immunization with monoclonal antibodies directed at TcdA and TcdB in patients who have acute C. difficile infection reduces the overall recurrence rate. 17 The incidence of C. difficile infection among hospitalized patients varies widely from year to year and in different locations but has generally been increasing, to almost 15 cases per 1000 hospital discharges 18 and approximately 20 cases per 100,000 person-years in the community 19 (Fig. 2 ). C. difficile infection was first recognized in Western Europe and North America, where the BI/NAP1/027 strain originated. However, C. difficile now has global reach, and epidemic strains can be found in diverse hospital settings. 20 
R isk Fac t or s
The most important risk factor for C. difficile infection remains antibiotic use. Ampicillin, amoxicillin, cephalosporins, clindamycin, and fluoroquinolones are the antibiotics that are most frequently associated with the disease, but almost all antibiotics have been associated with infection (Table 1) . Paradoxically, many predisposing antibiotics show at least some in vitro activity against C. difficile, and regimens including metronidazole can both incite the disease and provide effective treatment. 21 In hospitals and long-term care facilities, environmental contamination and frequent antibiotic usage are risk factors for infection. 22 The risk of C. difficile infection and the severity of infection increase as age increases 23, 24 (Fig. 2) . In one study, the risk of contracting C. difficile during an outbreak was 10 times as high among persons older than 65 years of age as among younger inpatients. 25 The majority of C. difficile infections are hospital-acquired, but community-acquired infection has increased dramatically in the past decade 26 and may now account for up to a third of new cases. 27 Community-acquired C. difficile is defined as disease onset in a person who had no overnight stay in a health care facility within 12 weeks before infection; the definition does not rule out acquisition in a health care facility. As compared with nosocomial infection, community-acquired C. difficile infection occurs in patients who are younger and more often have had no clear exposure to antibiotics or other known risk factors; major modes of acquisition of community-acquired infection remain to be elucidated. Furthermore, morbidity and mortality associated with community-acquired C. difficile infection are lower than those associated with nosocomial infection, because of the younger age and fewer coexisting conditions of the nonhospitalized population; however, up to 40% of patients with communityacquired infection require hospitalization, and rates of recurrence are similar among the two populations. 19, 27 The influence of acid suppression in C. difficile infection remains uncertain. In theory, gastric acid suppression should allow more vegetative organisms to reach the colon; however, C. difficile spores, the vectors for infection, are acid-resistant and remain viable at gastric pH. Some investigators have reported an increased risk of infection in association with acid suppression, 28 whereas others, after adjusting for coexisting conditions, have not confirmed an increased risk. 22, 29, 30 Other documented risk factors for infection include advanced age, inflammatory bowel disease, organ transplantation, chemotherapy, chronic kidney disease, immunodeficiency, and exposure to an infant carrier or infected adult. 19, 31 C. difficile infection is associated with severe illness, infection-related mortality of 5%, and all-cause mortality of 15 to 20%. 3, 32 Severe C. difficile infection, identified by a white-cell count greater than 15,000 per cubic millimeter, hypoalbuminemia, and acute kidney injury, is an independent predictor of urgent colectomy and death. 32, 33 Risk factors are similar to those for recurrent C. difficile infection and include advanced age, a severe initial episode of C. difficile infection, and on going use of antibiotics not directed at C. difficile. 34, 35 Di agnosis C. difficile infection is currently diagnosed either by enzyme immunoassay for toxins in stool or by DNA-based tests that identify the microbial toxin genes in unformed stool. Stool culture for C. difficile requires anaerobic culture and is not widely available. Enzyme immunoassay used to be the mainstay of testing for C. difficile infection, since it is rapid and easily performed. Recently, many hospital laboratories have adopted DNA-based tests that detect toxigenic strains and provide higher sensitivity and specificity than does enzyme immunoassay. Some DNA-based tests also detect the presence of the BI/NAP1/027 strain, a finding that may influence the choice of therapy, since fidaxomicin is associated with a reduction in the risk of recurrence of non-BI/ NAP1/027 strains only, as compared with vancomycin. DNA assays for C. difficile infection may appear to show a higher incidence of infection than earlier tests 36 because the high sensitivity of DNA assays allows for low levels of toxigenic organisms of uncertain clinical significance. The concern that DNA assays can detect clinically insignificant infections is supported by the results of recent studies that suggest that detection of toxigenic C. difficile by DNA testing in the absence of free toxin in the stool does not influ- The overall incidence of nosocomial C. difficile infection is shown by year (blue), as is the incidence according to patient age (black). Data are from Steiner et al. 18 T h e ne w e ngl a nd jou r na l o f m e dicine ence clinical outcomes. 33, 37 In the future, highly sensitive quantitative toxin assays may also contribute to diagnostic algorithms. Conversely, heterogeneous diagnostic tests and lack of clinical suspicion contribute to delayed diagnosis. 38 Sequential testing with the use of PCR and enzyme immunoassay has been advocated, 39 but in clinical practice, in a patient with diarrhea, positive results of either enzyme immunoassay or PCR assay should prompt treatment. Endoscopy is rarely required but may be helpful in patients with an overlapping condition such as inflammatory bowel disease. Conversely, the negative predictive value of PCR assay and enzyme immunoassay is more than 95% in average-risk groups, and negative results should prompt evaluation for other causes. 39 Stool testing for C. difficile toxins should be confined to patients with diarrhea. Although a substantial proportion of at-risk, hospitalized patients may be colonized, the testing and treatment of persons with solid stools is not recommended. Similarly, posttreatment testing has no role in confirming eradication. Many successfully treated patients will continue to test positive for weeks or months after the resolution of symptoms; additional treatment is neither required nor effective. 40 More difficult is the decision of when to test and treat patients who have mild ongoing or recurrent diarrhea after initial treatment. In such patients, stool testing can be helpful in differentiating recurrent C. difficile infection from postinfectious irritable bowel syndrome or inflammatory bowel disease that can be triggered by acute enteric infections.
Pr e v ention
In the absence of an effective vaccine, infection control has focused on antibiotic stewardship, prevention of spread in health care facilities, and probiotics. Minimizing antibiotic use has been successful in decreasing C. difficile infection in hospitalized patients. 41 The prohibiting of the routine use of ceftriaxone and ciprofloxacin accompanied by an educational campaign reduced the rate of C. difficile infection by 77% in a 450bed hospital in Scotland. 42 However, strict stewardship of antibiotics is labor-intensive and may not be effective in all settings. 41 C. difficile is nearly ubiquitous in health care facilities, and viable spores can be identified on the hands and stethoscopes of health care workers, on bedding, on telephones, in bathrooms, and on bedside furniture. 43 Using alcohol-based hand sanitizers does not reduce the number of viable C. difficile spores, whereas washing with soap and water does. 44 However, because the availability and convenience of hand-sanitizer solutions greatly increases overall adherence to hand hygiene, 45 alcohol-based preparations are likely to remain standard. Patients with known or suspected C. difficile infection should be isolated in a single room, and health care professionals should wear gloves and gowns and wash hands with soap and water; postdischarge disinfection of the room is also recommended. 46 The use of probiotics to prevent C. difficile colonization could be a safe and easily adoptable control strategy. Various strains of probiotics are effective for the prevention of noninfectious, 47 Initial studies evaluating the use of probiotics for control of antibiotic-associated diarrhea were underpowered for the detection of protection against C. difficile infection. More recent studies have shown mixed results, with a few studies showing that probiotics conferred significant protection in cohorts with unusually high rates of C. difficile infection 48, 49 and another study showing no protection in hospital inpatients who had low rates of infection. 50 At present, probiotics have an uncertain effect on the prevention of C. difficile infection, and their routine use for the prevention or treatment of active infection is not recommended.
Tr e atment of Acu te Infec tion
Metronidazole and oral vancomycin have been the mainstays of treatment for C. difficile infection since the 1970s, and despite their use by millions of patients, clinically important resistance to either vancomycin or metronidazole has not been reported. For the treatment of severe disease, vancomycin is better than metronidazole, but for mild-to-moderate infection, the two antibiotics have been considered to be equivalent. 51 However, a marked rise in clinical failure associated with metronidazole, especially in patients with the BI/NAP1/027 strain, has been seen in the past decade. 52 Previous studies were underpowered to evaluate differences between metronidazole and vancomycin in cases of nonsevere infection, but recent data suggest an overall superiority of vancomycin. Studies of tolevamer, a toxin-binding polymer, showed that with respect to curing acute C. difficile infection, tolevamer was inferior to vancomycin and to metronidazole, but the studies also showed that clinical success, defined as resolution of diarrhea, was lower with metronidazole than with vancomycin (73% vs. 81%, P = 0.02). 53 The superiority of vancomycin was observed in patients with mild disease, those with moderate disease, and those with severe disease. 53 These factors, along with the more frequent side effects associated with metronidazole and the decreasing cost of generic vancomycin, have led to increasing use of vancomycin. 54, 55 (Table 2 ).
In 2011, fidaxomicin, a poorly absorbed, bactericidal, macrocyclic antibiotic with activity against specific anaerobic gram-positive bacteria, was approved by the Food and Drug Admin-istration (FDA) for the treatment of C. difficile infection. In phase 3 clinical trials, the cure rate for acute infection was nearly equivalent among patients receiving fidaxomicin and those receiving vancomycin (approximately 90% for each), but the risk of recurrence was 15% among patients receiving fidaxomicin, as compared with 25% among those receiving vancomycin. 56, 57 However, a reduced risk of recurrence was not seen among patients infected with the BI/NAP1/027 strain, which was found in 38% of isolates. The markedly higher cost of fidaxomicin has limited its use, despite its superiority to vancomycin in reducing the risk of recurrence (Table 1) .
Tr e atment of R ecur r ent Infec tion
The risk of C. difficile recurrence ranges from 20% after an initial episode to 60% after multiple prior recurrences. 58, 59 The costs associated with recurrent infection may exceed those associated with primary infection. 60 Recurrence is most often due to reexposure to or reactivation of spores in patients who have an impaired immune response to infection and weakened barrier function of the colonic microbiota.
Antibiotic Treatment
Treatment of a first episode of recurrent infection with a repeat course of either metronidazole or vancomycin for 10 to 14 days is successful in approximately 50% of patients. 31, 34 Second and subsequent recurrences can be difficult to cure, primarily because of the persistence of spores in the bowel or environment and the inability of the patient to mount an effective immune response to C. difficile toxins, rather than to antibiotic resistance. 61 Second recurrences can be treated with fidaxomicin (200 mg twice a day for 10 days) or by a vancomycin regimen involving tapered (decreased over time) and pulsed (intermittent [i.e., every few days]) dosing ( Table 2 ). Recent data suggest that fidaxomicin may be more effective than vancomycin at preventing further episodes of C. difficile after an initial recurrence. 62 Options are limited for patients with severe colitis in whom vancomycin and fidaxomicin are ineffective. Emergency colectomy for fulminant C. difficile infection is associated with mortality as high as 80%, although a diverting ileostomy and a colonic lavage with vancomycin may be an T h e ne w e ngl a nd jou r na l o f m e dicine effective alternative. 63 Other antibiotics that have activity against C. difficile are rifaximin, nita zoxanide, ramoplanin, teicoplanin, and tigecycline. However, because of limited data, high cost, an unfavorable adverse-event profile, and resistance to C. difficile (associated with rifaximin in particular), the use of these agents is not recommended except in cases of unacceptable adverse effects associated with standard therapy, the need for salvage therapy for fulminant disease when surgery is not possible, and intractable recurrent infection (Table 2) .
Fecal Microbial Transplantation
The human colonic microbiota, which provides colonization resistance against bacterial patho-gens, is considered to be a key determinant in the pathogenesis of C. difficile. After a patient has had brief exposure to oral antibiotics, a rapid decline in fecal microbial diversity is common and may last many months. 64, 65 Stopping the administration of all antibiotics is the best way to eliminate C. difficile from the colon and allow the fecal microbiota to recover spontaneously. However, recovery may take 12 weeks or longer, during which patients may have a relapse. Fecal microbial transplantation, a procedure that was first reported in 1958, 66 has recently emerged as an accepted, safe, and effective treatment for recurrent C. difficile infection. The FDA initially suggested that an investigational new drug (IND) application would be necessary before treatment 54 and Cohen et al. 55 † C. difficile infection should be considered mild only if it occurs in outpatients. ‡ A tapered and pulsed regimen involves the administration of vancomycin as follows: 125 mg four times a day for 1 week, 125 mg three times a day for 1 week, 125 mg twice a day for 1 week, 125 mg daily for 1 week, 125 mg once every other day for 1 week, and 125 mg every 3 days for 1 week. clostridium difficile infection of C. difficile infection with fecal microbial transplantation but later ruled that it would allow fecal microbial transplantation for this indication without an IND application, although informed consent is still required. 67 The precise components of the fecal microbiome that provide resistance against C. difficile are not known, but the phyla Bacteroidetes and Firmicutes are thought to comprise critical components of the material that needs to be transplanted. 68, 69 The oral or rectal transplantation of feces from a healthy, pretested donor and the simultaneous cessation of all antibiotic use in the recipient are successful in treating more than 90% of patients with recurrent C. difficile infection. 70 Although the transmission of an undetected or unidentifiable pathogen from the donor is a possibility, there are no known reports of serious infectious complications resulting from fecal microbial transplantation that was performed with appropriate donor screening. In 2013, the results of a randomized, controlled trial of fecal microbial transplantation were reported. 71 The trial showed that the administration of vancomycin followed by an infusion of donor feces delivered by nasoduodenal tube was safe and superior to vancomycin alone for recurrent C. difficile infection (Fig. 3) .
Given the efficacy of fecal microbial transplantation for recurrent infection, there has been growing interest in its use for severe primary disease. 72 To date, there are few studies about this treatment approach, and although case series are promising, 72, 73 more work is needed to understand the possible role of fecal microbial transplantation in primary C. difficile infection. In addition, efforts to develop a suitable mixture of cultured fecal bacteria as a substitute for stool in fecal microbial transplantation are under way. Capsules administered orally that contain the spores of fecal bacteria have shown efficacy in treating recurrent disease and warrant further testing as a substitute. 74
Immuniz ation
Results of the immunization of animals with toxoids TcdA and TcdB 75 and findings showing the protective effect of naturally acquired serum IgG antitoxins in patients colonized with C. difficile suggest the potential for vaccination of humans against C. difficile infection. 15, 76 Passive immunization with monoclonal antibodies to C. difficile toxins also provides substantial protection from recurrence after acute infection and may be cost-effective in patients who are at high risk for recurrence. 17 Vaccination against the toxins of C. difficile offers the possibility of an effective and rela- Among patients with recurrent C. difficile infection, the rate of cure without relapse was higher among those who received an infusion of donor feces than among those who received vancomycin with or without bowel lavage (Panel A). Fecal microbial diversity in recipients before and after the infusion of donor feces is compared with the diversity in healthy donors (Panel B T h e ne w e ngl a nd jou r na l o f m e dicine tively inexpensive approach to prevention. Initial phase 1 studies have shown strong antitoxin responses in healthy volunteers immunized with toxoids of TcdA and TcdB. 77 At least two international, placebo-controlled studies are currently under way to test the immunogenicity, safety, and efficacy of vaccination for the prevention of nosocomial C. difficile infection (ClinicalTrials.gov numbers, NCT01887912 and NCT02117570). The larger of these trials involves the administration of three doses of toxoid vaccine or placebo in 15,000 study participants and an evaluation of the risk of acute disease over the course of 3 years. It is unclear whether vaccination will be used for primary or secondary prevention and whether vaccination will prevent or lessen the severity of clinical infection. Clinical use will depend on numerous variables, including safety, efficacy, and cost-effectiveness, as well as improved ability to predict the risk of C. difficile infection. In addition, neither vaccination nor the administration of monoclonal antibodies is likely to eliminate colonization, so isolation of patients will still be necessary to prevent transmission. Nevertheless, if studies are positive, it is likely that vaccination will become prevalent.
Summ a r y
Despite concerted efforts to improve the prevention and treatment of C. difficile infection, this infection remains common and serious in both hospitals and the community. In recent years, fecal microbial transplantation has emerged as a safe and very effective strategy for the treatment of recurrent infection. With further refinement, fecal microbial transplantation will most likely become the standard of care for recurrent infection. Newer antibiotics with clinical activity against C. difficile are now available, but widespread use has been limited by their cost, which is higher than the cost of vancomycin. Although antibiotic stewardship and decontamination in health care settings remain essential for infection control, effective probiotics and vaccination will most likely become important tools for the prevention of C. difficile infection in the future. Until such time, C. difficile infection will continue to be a common and highly morbid consequence of antibiotic use.
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